![Iris Tavor](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Iris Tavor
Consigliere Generale presso ENLIVEX THERAPEUTICS LTD.
Posizioni attive di Iris Tavor
Società | Posizione | Inizio | Fine |
---|---|---|---|
ENLIVEX THERAPEUTICS LTD. | Consigliere Generale | - | - |
Storia della carriera di Iris Tavor
Precedenti posizioni note di Iris Tavor
Società | Posizione | Inizio | Fine |
---|---|---|---|
Pluristem Ltd.
![]() Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Consigliere Generale | - | - |
Statistiche
Distribuzione geografica
Israele | 3 |
Posizioni
General Counsel | 2 |
Settori
Health Technology | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ENLIVEX THERAPEUTICS LTD. | Health Technology |
Aziende private | 1 |
---|---|
Pluristem Ltd.
![]() Pluristem Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003. | Commercial Services |
- Borsa valori
- Insiders
- Iris Tavor
- Esperienza